
EPO: Intermediate Generalisations in Pharma Patents Trigger Added Matter
Summary
- Intermediate generalisations are a frequent cause of added matter objections at the European Patent Office.
- This issue arises when a feature is taken from a worked example and put into a claim without the rest of the example.
- The resulting claim scope is neither as broad as the general disclosure nor as narrow as the specific example.
- Examples discussed in this context often detail complete products.
The Challenge of Intermediate Generalisations
Patent attorneys drafting pharmaceutical patent applications before the EPO must be acutely aware of the 'intermediate generalisation' trap to avoid added matter objections.
Intermediate generalisations represent a persistent and well-recognized challenge leading to "added matter objections EPO" within the European patent system. This specific issue arises when a particular feature is selectively extracted from a detailed "worked example" presented within a patent application and subsequently incorporated into a claim, yet without including the other constituent elements of that same example. For "pharma patents," where detailed examples often illustrate complex formulations or processes for "complete products," this can be a particularly intricate drafting pitfall.
The consequence of such an intermediate generalisation is a patent claim whose scope is problematic. It fails to align with either the broad, overarching general disclosure provided in the patent specification or the precise, narrow confines of the original worked example from which the feature was derived. Instead, the claim occupies an ambiguous middle ground, creating a scope that is neither fully supported by the general teaching nor strictly limited to the specific embodiment. This lack of clear support for the intermediate scope is precisely what triggers "added matter objections EPO," indicating that the subject matter claimed extends beyond what was originally disclosed in the application as filed.
Legal Context and Pharmaceutical Patent Drafting
The concept of "added matter objections EPO" is fundamental to maintaining the integrity of the patent system, ensuring that the scope of protection granted does not exceed the technical contribution originally disclosed. For "pharma patents," the detailed "patent specification disclosure" is paramount, as it must enable a skilled person to reproduce the invention across the claimed scope. When "pharmaceutical patent examples" are provided, they serve to illustrate the invention's practical application and often demonstrate specific embodiments of a drug, formulation, or treatment method.
The problem of "EPO intermediate generalisations pharma patents" becomes acute because these examples, which often describe "complete products" or processes, are frequently relied upon to support broader claims. However, simply lifting a single characteristic from such an example without its accompanying context can create a claim that appears to be a new invention, not directly and unambiguously derivable from the original disclosure. This directly implicates "EPO patentability issues," as claims must be supported by the description and must not introduce new subject matter. Effective "patent claim drafting EU" therefore demands a rigorous approach to how specific features from examples are generalized.
Strategic Claim Drafting to Avoid Pitfalls
To navigate these complexities, patent attorneys drafting pharmaceutical patent applications before the EPO must be acutely aware of the 'intermediate generalisation' trap. This awareness is crucial for successful "patent claim drafting EU," particularly when seeking protection for "pharma patents." The challenge lies in striking the right balance between claiming a sufficiently broad scope and ensuring that every element of the claim is directly and unambiguously derivable from the initial "patent specification disclosure."
Careful consideration is therefore essential when incorporating features from "worked examples" into claims. Attorneys must ensure that any generalization of a feature from a specific embodiment is consistently supported by the broader technical teaching of the application, and not merely an arbitrary extraction. The goal is to avoid creating a claim that represents an intermediate scope for which there is no explicit or implicit basis in the original filing, thereby sidestepping the significant hurdle of "added matter objections EPO" and safeguarding the patent's validity.
Practical Implications
Patent attorneys drafting pharmaceutical patent applications before the EPO must be acutely aware of the 'intermediate generalisation' trap to avoid added matter objections. This requires careful consideration of how features from worked examples are incorporated into claims, ensuring the scope is consistently supported by the general disclosure and not merely an arbitrary extraction from a specific embodiment.
Source
How does this affect you?
Get an AI analysis of this article grounded in your jurisdictions, practice areas, and any policy documents you've uploaded to Wansom.
Finish Reading the Full Story and the Expert Analysis.
Get the latest legal & regulatory intelligence in European Union
Wansom is AI and can make mistakes.
